Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Adherence higher, discontinuation lower with ixekizumab vs secukinumab
07 Mar 2022
Psoriasis patients treated with ixekizumab show better persistence and adherence over 24 months as well as a lower risk of discontinuation than those using secukinumab, reports a recent study that used real-world data.
07 Mar 2022

Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
07 Mar 2022
bởiChristina Lau
Adding capecitabine to adjuvant chemotherapy containing docetaxel, epirubicin and cyclophosphamide significantly improves 15-year overall survival (OS) in patients with early breast cancer, results of the phase III FinXX trial (Finland Capecitabine Trial) have shown.
07 Mar 2022






